Qankorey was founded in 2014, and headquartered in Changsha of Hunan, the rising star of central China. The R&D center is located in Melbourne, Australia. It is a Sino-foreign joint venture focusing on the research of cutting-edge medical technology, a national high-tech enterprise, a governing unit of China Association for Alzheimer's Disease, Changsha"Help Our Motherland through Elite Intellectual Resources from Overseas"(HOME Program) Workstation. Research innovation, clinical service.

Qankorey cooperates with top Australian scientific research institutes Florey. Florey Institute of Neuroscience and Mental Health, Global Flagship Study of Alzheimer's Disease and Australian Imaging, Biomarker & Lifestyle Flagship Study of Aging (AIBL). We focus on global medical problems, researching the key technologies of prevention, screening, diagnosis and treatment of Alzheimer's disease.

Enters into industry-university-research cooperation with several national clinical research centers for geriatrics, maintains strategic partnership with National Clinical Research Center for Geriatrics, carries out scientific research cooperation on the technology of prevention, control and transformation of geriatric diseases, and establishes an international exchange platform combining scientific research with clinical practice and achievement transformation.

Qankorey has made the product development layout of the whole, industry chain of Alzheimer's disease from early urine screening, quantitative diagnosis of chemiluminescence in urine, blood and cerebrospinal fluid, accurate prediction of somatic cells and genes to intervention and treatment drugs. It undertakes more than ten major projects of the Ministry of Science and Technology, province and city, and has more than 160 intellectual property rights, such as patents and software.

Qankorey will keep its mission firmly in mind serve the public health, revitalize industry development, create a national medical brand with international influence.